Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer

Abstract

PURPOSE:

To investigate the association between the HER2 germline mutation Ala270Ser (A270S), located in HER2 extracellular domain, and survival in breast cancer patients.

METHODS:

HER2 germline mutation A270S was identified in 5395 consecutive patients with operable primary breast cancer using direct Sanger sequencing analysis. Survival curves for patients with HER2 A270S mutation were compared using the Kaplan-Meier method with log-rank test.

RESULTS:

We identified that 31 cases carried HER2 germline mutation A270S in 5395 patients (0.6%, 31/5395). The HER2 A270S mutation was significantly associated with recurrence-free survival (RFS) and distant recurrence-free survival (DRFS) in the entire cohort of 5395 patients (RFS, unadjusted hazard ratio [HR] $=$ 2.23; 95% confidence interval [CI] $=$ 1.00–5.00; $P=$ 0.045; DRFS, unadjusted HR $=$ 2.80; 95% CI $=$ 1.25–6.28; $P=$ 0.009). Among the HER2-negative patients ( $n=$ 3825), those with the HER2 A270S mutation had a significantly worse RFS (unadjusted HR $=$ 3.19; 95% CI $=$ 1.42–7.16; $P=$ 0.003) and DRFS (unadjusted HR $=$ 3.98; 95% CI $=$ 1.77–8.96; $P<$ 0.001) than did those with wild type. Moreover, the A270S mutation remained an independent unfavorable factor for RFS and DRFS in the HER2-negative patients (RFS, HR $=$ 3.30; 95% CI $=$ 1.34–8.10; $P=$ 0.009; DRFS, HR $=$ 4.26; 95% CI $=$ 1.73–10.47; $P=$ 0.002).

CONCLUSIONS:

Breast cancer patients with the HER2 germline mutation A270S had a worse survival, especially in HER2-negative patients. Therefore, HER2-negative patients with a HER2 germline mutation A270S might be potential candidates for HER2-targeted therapy.

Keywords

Breast cancer prognosis HER2 germline mutation

1. Introduction

The HER2 (human epidermal growth factor receptor 2) gene (also known as erbB-2 or neu) encodes a transmembrane glycoprotein with tyrosine kinase activity. HER2 gene is a member of the epidermal growth factor receptor (EGFR) family and plays an important role in the regulation of cell growth, differentiation, and invasion [1, 2]. The HER2 protein is composed of four domains: extracellular domain (ECD), transmembrane domain (TMD), tyrosine kinase domain (TKD) and the carboxy tail [3, 4].The cysteine-rich domain (CR1) is a secondary structure element of extracellular region that plays a crucial role in HER2 dimerization [5, 6].

It is well-known that HER2 gene amplification is associated with worse clinical outcome in breast cancer [7, 8, 9, 10]. HER2-targeted therapy, i.e., trastuzumab, significantly improves the survival in HER2-positive breast cancer [11, 12, 13, 14]. Although HER2 amplification and/or overexpression was associated with poor survival, the prognostic value of HER2 gene mutation in breast cancer was unclear. Recently, Yamamoto et al. identified a novel germline mutation (G660D, GGC to GAC) in the transmenbrane domain of HER2 in lung cancer [15]. Mutant HER2G660D protein was more stable than wild-type proteinand activated Akt, and may be oncogenic, causing lung adenocarcinomas [15]. In our previous study, we found that HER2 Ile655Val polymorphism could affect the function of HER2 gene restricted in HER2-positive breast cancers. Patients with Val variant had an aggressive phenotype and were sensitive to trastuzumab treatment [16]. These inspired us to explore HER2 germline mutation in breast cancer and its significance in survival prediction and targeted therapy. We initially screened all exons of the HER2 gene in 1000 patients with breast cancer and found 6 patients with a novel germline mutation A270S (c.808G>T, p.Ala270Ser, located in Chromosome 17: 39710388). Codon 270 is located in CR1, especially in the dimerization and pertuzumab binding interface [17]. So missense mutation A270S of the codon 270 may affect the function of HER2 protein or biological effects of pertuzumab applying to HER2 protein.

Therefore, to identify the clinical effects of the HER2 germline mutation A270S, we identified A270S mutation in a relatively large cohort of 5395 women with operable primary breast cancer, and analyzed the association between A270S mutation and survival in 5395 breast cancer patients, especially in HER2-negative patients.

2. Patients and methods

2.1 Patients

A total of 5681 patients with operable primary breast cancer were treated at the Breast Center, Peking University Cancer Hospital from October 2003 to December 2013. Of these 5681 patients, the result of HER2 mutation status was not obtained due to the poor quality of the DNA samples in 181 patients, and follow up was not available for 95 patients. Thus, 5395 patients with primary breast cancer were included in this study. Ages at diagnosis of the patients ranged from 19 to 90 years, with a median age of 50 years. The stage of the tumors was classified according to the tumor-node-metastasis classification of the Union Internationale Contre Le Cancer. Tumor size was defined as the maximum tumor diameter measured by ultrasound at the time of diagnosis. Tumor grade, tumor size, HER2 status, estrogen receptor (ER) status, progesterone receptor (PR) status and adjuvant therapy were obtained from review of medical records, and all are shown in Table 1. Informed consent was obtained from all individual participants and this study was approved by the Research and Ethics Committee of Peking University Cancer Hospital.

Table 1
Association between HER2 germline mutation A270S and clinicopathologic characteristics in the entire cohort ( $n=$ 5395)

Characteristics	Overall	Wide type		Mutated		$P$
		N (%)		N (%)
Total	5395	5364	(99.4)	31	(0.6)
Age at diagnosis
$\leqslant$ 40 yr	950	942	(17.6)	8	(25.8)	0.23
$>$ 40 yr	4445	4422	(82.4)	23	(74.2)
Tumor size
$<$ 2 cm	2206	2196	(42.9)	10	(32.3)	0.23
$\geqslant$ 2 cm	2947	2926	(57.1)	21	(67.7)
Unknown	242	242		0
Tumor grade
I	603	602	(13.3)	1	(4.2)	0.22
II	3349	3331	(73.7)	18	(75.0)
III	590	585	(12.9)	5	(20.8)
Unknown	853	846		7
Lymph nodes
Positive	1943	1931	(38.3)	12	(41.4)	0.73
Negative	3132	3115	(61.7)	17	(58.6)
Unknown	320	318		2
ER status
Positive	3833	3813	(72.8)	20	(69.0)	0.65
Negative	1437	1428	(27.2)	9	(31.0)
Unknown	125	123		2
PR statuss
Positive	3385	3367	(64.3)	18	(62.1)	0.81
Negative	1884	1873	(35.7)	11	(37.9)
Unknown	126	124		2
HER2 status
Positive	1219	1213	(24.2)	6	(21.4)	0.73
Negative	3825	3803	(75.8)	22	(78.6)
Unknown	351	348		3
Trastuzumab use
Yes	302	302	(5.6)	0	(0)	0.42
No	5093	5062	(94.4)	31	(100)
Adjuvant therapy
C	2018	2012	(35.7)	6	(19.4)	0.08
E	1038	1032	(23.1)	6	(19.4)
C plus E	1736	1720	(30.5)	16	(51.6)
No therapy	603	600	(10.6)	3	(9.7)

ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; C: chemotherapy; E: endocrine therapy; C plus E: chemotherapy plus endocrine therapy.

2.2 Determination of HER2 germline mutation A270S

The blood samples were collected form breast cancer patients treated at the Breast Center, Peking University Cancer Hospital. Genomic DNA was isolated from peripheral blood leukocytes using a phenol-chloroform assay. The HER2 germline mutation A270S was identified by Sanger-sequencing. Amplification of DNA fragments was performed by polymerase chain reaction (PCR) in a thermocycler (Gene CyclerTM, Bio-rad, Hercules, CA, USA) in 20 $\mu$ l of solution containing 30 ng of genomic DNA, 2.5 mM MgCl ${}_{2}$ , 0.8 mM dNTP, 1.0 $\times$ PCR buffer, 0.5 $\mu$ M forward and reverse primers, and 1.25 unit AmpliTaq DNA polymerase (Promega, USA). The reaction condition was first 94 ${}^{\circ}$ C for 5 min to activate Taq DNA polymerase, followed by denaturation at 94 ${}^{\circ}$ C for 30 sec, annealing at 66 ${}^{\circ}$ C for 30 sec, and extension at 72 ${}^{\circ}$ C for 45 sec. The PCR was run for 35 cycles and finally elongated for 10 min. The forward primer sequence was: 5’-GCCTGGTATGTGCCTCTGCT-3’, and the reverse primer sequence was: 5’-GCTGCCTC TCCTTACTGCCA-3’. All fragments were sequenced using BigDye Terminator Cycle Sequencing Kit and ABI 3730 automated sequencer (Applied Biosystems, Foster City, CA). Compareing with the reference sequence (NM_004448.2) to find the A270S mutation. All patients with A270S mutation were confirmed in duplicate.

2.3 HER2 Status

The HER2 status was determined by immunostaining according to a standard method: a score of 0 and 1 $+$ was considered negative and score of 3 $+$ was considered positive; a score of 2 was further evaluated by fluorescence in situ hybridization (FISH) using the Vysis kit (Vysis, Inc., Downers Grove, IL, USA) according to the manufacturer’s instructions as described previously [18].

2.4 Statistical analysis

The associations between the HER2 A270S mutation and clinicopathologic characteristics in the entire cohort were evaluated using Pearson Chi-Square test. Survival curves were derived from Kaplan-Meier analysis and the differences between the curves were compared by log-rank tests. Recurrence-free survival (RFS) was defined as the time from the date of pathological diagnosis to the date when locoregional recurrence or metastases, distant metastases or death from breast cancer. Distant recurrence-free survival (DRFS) was defined as the time from diagnosis to the occurrence of distant metastasis or death for which breast cancer was the primary or underlying cause. The Cox proportional hazards model was used to determine the association between HER2 A270S mutation and the risk of local/distant recurrence or death after adjustments for patient and tumor characteristics. All statistical tests were two sided, and $P$ -values of $<$ 0.05 were considered statistically significant. The statistical analysis was performed using the SPSS software package 20.0 for Windows (SPSS Inc., Chicago, IL, USA).

3. Results

3.1 Patient characteristics

A total of 5395 patients with primary breast cancer were included in this study. The clinicopathological characteristics of these patients are presented in Table 1. Totally, HER2 germline mutation A270S was found in 31 (0.6%, 31/5395) patients (Fig. 1). Among these 31 breast cancer patients, 6 patients were HER2-positive, 22 patients were HER2-negative, and 3 were unknown.

Figure 1.

Genotyping the HER2 A270S mutation by DNA sequencing assay. (a) Wild type; (b) A270S mutation.

There was no significant difference with respect to age, tumor size, tumor grade, lymph node status, ER status, PR status, HER2 status, adjuvant therapy, and trastuzumab treatment between the breast cancer patients with A270S mutation and non-carreriers in this cohort of 5395 patients (Table 1).

Table 2

Multivariate analyses of RFS and DRFS in the entire 5395 breast cancer patients

Variables	RFS			DRFS
	HR (95% CI)	$P$		HR (95% CI)	$P$
Codon 270
(Mutated vs Wild type)	2.28 (0.94–5.55)	0.	07	2.90 (1.19–7.06)	0.	019
Age at diagnosis
( $\leqslant$ 40 yr vs $>$ 40 yr)	1.43 (1.11–1.86)	0.	019	1.31 (0.98–1.76)	0.	07
Tumor size
( $\geqslant$ 2 cm vs $<$ 2 cm)	2.03 (1.56–2.64)	$<$ 0.	001	2.08 (1.55–2.79)	$<$ 0.	001
Tumor grade
(III vs I or II)	1.00 (0.72–1.39)	0.	99	1.06 (0.74–1.52)	0.	76
Lymph nodes
(positive vs negative)	3.50 (2.75–4.46)	$<$ 0.	001	4.03 (3.06–5.30)	$<$ 0.	001
ER status
(negative vs positive)	1.60 (1.17–2.19)	0.	003	1.53 (1.09–2.16)	0.	015
PR status
(negative vs positive)	1.1 (1.08–2.00)	0.	013	1.44 (1.03–2.02)	0.	033
HER2 status
(positive vs negative)	1.11 (0.86–1.44)	0.	43	1.13 (0.85–1.51)	0.	39
Adjuvant therapy
(yes vs none)	0.66 (0.35–1.24)	0.	20	0.85 (0.45–1.61)	0.	62

RFS: Recurrence-free survival; DRFS: Distant Relapse-free survival; HR: hazard ratio; CI: confidence interval; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; vs: versus.

Figure 2.

Kaplan-Meier estimate of (a) recurrence-free survival (RFS) and (b) distant recurrence-free survival (DRFS) in the entire study population of 5395 patients, according to HER2 germline mutation A270S.

3.2 HER2 A270S mutation and survival

The median follow-up was 51 months (ranged from 1 to 195 months). The estimated 5-year RFS and DRFS in the 5395 patients were 91.3% (95% confidence interval [CI] $=$ 90.5%–92.1%) and 92.9% (95% CI $=$ 92.1%–93.7%), respectively. Patients with the HER2 germline mutation A270S had a significant worse RFS (unadjusted hazard ratio [HR] $=$ 2.23; 95% CI $=$ 1.00–5.00; $P=$ 0.045) and DRFS (unadjusted HR $=$ 2.80; 95% CI $=$ 1.25–6.28; $P=$ 0.009) compared with the patients with the wild type HER2 in 5395 patients (Fig. 2). Furthermore, multivariate analysis revealed that the A270S mutation remained as a significantly unfavorable factor for DRFS (adjusted HR $=$ 2.90; 95% CI $=$ 1.19–7.06; $P=$ 0.019) after adjustment for age, tumor grade, tumor size, lymph node status, ER status, PR status, HER2 status and adjuvant therapy (Table 2).

Table 3
Multivariate analyses of RFS and DRFS in the 3825 HER2-negative breast cancer patients

Variables	RFS			DRFS
	HR (95% CI)	$P$		HR (95% CI)	$P$
Codon 270
(Mutated vs Wild type)	3.30 (1.34–8.10)	0.	009	4.26 (1.73–10.47)	0.	002
Age at diagnosis
( $\leqslant$ 40 yr vs $>$ 40 yr)	1.46 (1.07–1.98)	0.	016	1.41 (1.01–1.98)	0.	044
Tumor size
( $\geqslant$ 2 cm vs $<$ 2 cm)	2.42 (1.76–3.34)	$<$ 0.	001	2.54 (1.77–3.62)	$<$ 0.	001
Tumor grade
(III vs I or II)	1.00 (0.67–1.50)	0.	99	1.02 (0.65–1.59)	0.	93
Lymph nodes
(positive vs negative)	3.61 (2.70–4.84)	$<$ 0.	001	3.90 (2.82–5.40)	$<$ 0.	001
ER status
(negative vs positive)	1.89 (1.31–2.72)	0.	001	1.90 (1.28–2.83)	0.	002
PR status
(negative vs positive)	1.63 (1.16–2.30)	0.	005	1.50 (1.03–2.18)	0.	037
Adjuvant therapy
(yes vs none)	0.77 (0.39–1.51)	0.	44	0.98 (0.50–1.93)	0.	95

RFS: recurrence-free survival; DRFS: distant recurrence-free survival; HR: hazard ratio; CI: confidence interval; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; vs: versus.

Figure 3.

Kaplan-Meier estimate of (a) recurrence-free survival (RFS) and (b) distant recurrence-free survival (DRFS) in the 3825 HER2-negative patients, according to HER2 germline mutation A270S.

3.3 HER2 A270S mutation and survival in HER2-negative breast cancer

The HER2 expression status was available for 5044 of 5395 patients. Of these, 1219 (24%) were HER2-positive breast cancer patients, 3825 (76%) were HER2-negative patients (Table 1). In the HER2-negative patients, those with the HER2 A270S mutation had worse RFS (unadjusted HR $=$ 3.19; 95% CI $=$ 1.42–7.16; $P=$ 0.003) and DRFS (unadjusted HR $=$ 3.98; 95% CI $=$ 1.77–8.96; $P<$ 0.001) than those with the wild type (Fig. 2). Furthermore, multivariate analysis revealed that HER2 germline mutation A270S remained as a significantly unfavorable factor for RFS (adjusted HR $=$ 3.30; 95% CI $=$ 1.34–8.10; $P=$ 0.009) and DRFS (adjusted HR $=$ 4.26; 95% CI $=$ 1.73–10.47; $P=$ 0.002) (Table 3) after adjustment for age, tumor grade, tumor size, lymph node status, ER status, PR status and adjuvant therapy.

Among the 1219 HER2-positive breast cancer patients, only 6 patients harbored HER2 A270S mutation, statistical analysis was not conducted as a result of the underlying major bias. In addition, all the 6 patients had not been treated with HER2-targeted therapy, so it is very regrettable that we could not evaluate whether the mutation A270S would influence the biological effects of HER2-targeted therapy.

4. Discussion

In this study, we found 31 (0.6%) patients with HER2 germline mutation A270S in a relatively large cohort of 5395 unselected breast cancer patients. The mutation A270S was associated with a worse RFS and DRFS than the wild type in the total cohort of 5395 breast cancer patients and especially in the HER2-negative breast cancer patients ( $n=$ 3825), and the mutation A270S remained an independent unfavorable factor for RFS and DRFS in the HER2-negative patients. The cysteine-rich domain (CR1) is a secondary structure element of extracellular region and contributes $>$ 90% of the driving energy for dimerization of the extracellular region [5]. The HER2 A270S mutation which located in CR1 domain maybe an alternative mechanism to active HER2 in breast cancer.

It was well-known that patients with HER2-positive breast cancer had a relatively unfavorable survival compared with the HER2-negative patients [10, 19, 20]. Clinical application of HER2-targeted monoclonal antibody has significantly improved the survival of HER2-positive breast cancer patients [11, 12, 13]. Although HER2-negative breast cancer patients have a relatively more favorable survival than HER2-positive patients, a minority of HER2-negative patients may still suffer from metastases after treatment [19, 21]. Absence of an effective target drug like trastuzumab for HER2-positive breast cancer, is still a major adverse factor in the therapy of HER2-negative breast cancer. Identification of HER2 gene mutation may open up new avenues for treatment of HER2 negative breast cancer precisely.

HER2 mutations might be employed as treatment targets in patients with HER2-negative breast cancer [22]. Recent studies suggested that the HER2-targeted drugs trastuzumab and lapatinib inhibit the growth of cells with HER2 mutation in vitro and in vivo [22, 23, 24]. Oncogenic HER2 kinase domain mutations occur at low frequency in lung and breast cancer, and the HER2 gene mutations were found predominantly in HER2-negative patients [22, 25, 26]. Recently, recurring HER2 extracellular domain mutations in breast and lung cancer have been identified [27]. A phase II study of neratinib (an investigational irreversible oral tyrosine kinase inhibitor) in metastatic HER2 negative breast cancer with HER2 mutation was launched in 2012 (NCT01670877). An open-label, phase II study exploring the efficacy and safety of neratinib therapy in patients with solid tumors (breast, lung bladder colorectal biliary endometrial ovarian cancer) with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification has also been lunched in 2013 (NCT01953926). These clinical trials indicated that HER2 mutations might play an important role in HER2-targeted therapy of HER2 negative breast cancer patients.

This study has several limitations. First, although the cohort in this study is large, the number of individuals with HER2 A270S mutation is relatively small; particularly when the mutation carriers were stratified by HER2 expression status. In addition, the HER2-positive patients with A270S mutation had not been treated with HER2-targeted therapy, therefore, the results are premature and should be interpreted cautiously.

In summary, breast cancer patients with the HER2 germline mutation A270S had a worse survival, especially in HER2-negative breast cancer patients. HER2 germline mutation A270S might be a target for therapy of HER2-negative patients in the future. Further functional and independent studies are warranted to confirm our findings.

Footnotes

Conflict of interest

The authors have declared no conflicts of interest.

Funding

This study was funded by the 973 project (2013CB 911004), and the National Natural Science Foundation of China (30973436 and 81071629).

References

Akiyama

Sudo

Ogawara

et al., The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity, Science 232(4758) (1986), 1644–1646.

Yarden

and Sliwkowski

M.X.

, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol 2(2) (2001), 127–137.

Fleishman

S.J.

Schlessinger

and Ben-Tal

, A putative molecular-activation switch in the transmembrane domain of erbB2, Proc Natl Acad Sci USA 99(25) (2002), 15937–15940.

Lemmon

M.A.

Schlessinger

and Ferguson

K.M.

, The EGFR family: not so prototypical receptor tyrosine kinases, Cold Spring Harb Perspect Biol 6(4) (2014), a020768.

Dawson

J.P.

Berger

M.B.

Lin

C.C.

et al., Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface, Mol Cell Biol 25(17) (2005), 7734–7742.

Ogiso

Ishitani

Nureki

et al., Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains, Cell 110(6) (2002), 775–787.

Slamon

Clark

Wong

et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235(4785) (1987), 177–182.

Toikkanen

Helin

Isola

et al., Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up, J Clin Oncol 10(7) (1992), 1044–1048.

Seshadri

Firgaira

F.A.

Horsfall

D.J.

et al., Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group, J Clin Oncol 11(10) (1993), 1936–1942.

10.

Sjogren

Inganas

Lindgren

et al., Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers, J Clin Oncol 16(2) (1998), 462–469.

11.

Piccart-Gebhart

M.J.

Procter

Leyland-Jones

et al., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med 353(16) (2005), 1659–1672.

12.

Romond

E.H.

Perez

E.A.

Bryant

et al., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, New England Journal of Medicine 353(16) (2005), 1673–1684.

13.

Slamon

Eiermann

Robert

et al., Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med 365(14) (2011), 1273–1283.

14.

Gianni

Dafni

Gelber

R.D.

et al., Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial, Lancet Oncol 12(3) (2011), 236–244.

15.

Yamamoto

Higasa

Sakaguchi

et al., Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas, J Natl Cancer Inst 106(1) (2014), djt338.

16.

Han

Diao

et al., Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer, Ann Oncol 25(6) (2014), 1158–1164.

17.

Franklin

M.C.

Carey

K.D.

Vajdos

F.F.

et al., Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex, Cancer Cell 5(4) (2004), 317–328.

18.

Yao

Liu

et al., HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer, Ann Oncol 22(6) (2011), 1326–1331.

19.

Slamon

D.J.

Clark

G.M.

Wong

S.G.

et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235(4785) (1987), 177–182.

20.

Press

M.F.

Bernstein

Thomas

P.A.

et al., HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas, J Clin Oncol 15(8) (1997), 2894–2904.

21.

Paik

Bryant

Tan-Chiu

et al., HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15, J Natl Cancer Inst 92(24) (2000), 1991–1998.

22.

Bose

Kavuri

S.M.

Searleman

A.C.

et al., Activating HER2 mutations in HER2 gene amplification negative breast cancer, Cancer Discov 3(2) (2013), 224–237.

23.

Rexer

B.N.

Ghosh

Narasanna

et al., Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2, Clin Cancer Res 19(19) (2013), 5390–5401.

24.

Serra

Vivancos

Puente

X.S.

et al., Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation, Cancer Discov 3(11) (2013), 1238–1244.

25.

Stephens

Hunter

Bignell

et al., Lung cancer: intragenic ERBB2 kinase mutations in tumours, Nature 431(7008) (2004), 525–526.

26.

Shigematsu

Takahashi

Nomura

et al., Somatic mutations of the HER2 kinase domain in lung adenocarcinomas, Cancer Res 65(5) (2005), 1642–1646.

27.

Greulich

Kaplan

Mertins

et al., Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2, Proc Natl Acad Sci USA 109(36) (2012), 14476–14481.

Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer

Abstract

PURPOSE:

METHODS:

RESULTS:

CONCLUSIONS:

Keywords

1. Introduction

2. Patients and methods

2.1 Patients

Table 1 Association between HER2 germline mutation A270S and clinicopathologic characteristics in the entire cohort ( n = 5395)

2.3 HER2 Status

2.4 Statistical analysis

3. Results

3.1 Patient characteristics

Table 3 Multivariate analyses of RFS and DRFS in the 3825 HER2-negative breast cancer patients

4. Discussion

Footnotes

Conflict of interest

Funding

References

Table 1
Association between HER2 germline mutation A270S and clinicopathologic characteristics in the entire cohort ( $n=$ 5395)

Table 3
Multivariate analyses of RFS and DRFS in the 3825 HER2-negative breast cancer patients